MEDICAL GRAND ROUNDS

PARKLAND MEMORIAL HOSPITAL

November 9, 1967

THE EFFECT OF ORAL CONTRACEPTIVE AGENTS AND STEROIDS ON LIVER FUNCTION

Jaundice induced by 17 α methyl testosterone (Methyl testosterone)

1. Werner, S.C. Clinical syndromes associated with gonadal failure in men. Amer. J. Med. 3:52-66, 1947.

2. Werner, S.C., Hanger, F.M., and Kritzler, R.A. Jaundice during methyl testosterone therapy. Amer. J. Med. 8:325-331, 1950.

3. Koszalka, M.F. Medical obstructive jaundice. Report of a death due to methyl testosterone. The Journal Lancet 77:51-54, 1957.

4. Foss, G.L. and Simpson, S.L. Oral methyl testosterone and jaundice. Brit. Med. J. 1:259-262, 1959.

Jaundice induced by 17 α methyl-19-nortestosterone (Methylestrenolone)

5. Peters, J.H., Randall, A.H. Jr., Mendeloff, J., Peace, R., Coberly, J.C., and Hurley, M.B. Jaundice during administration of methylestrenolone. J. Clin. Endocrinol. and Metabol. 18:114-115, 1958 (Letter to editor).

6. Seelen, J.C. Complications during administration of methylestrenolone. J. Clin. Endocrinol. and Metabol. 18:1137-1138, 1958 (Letter to editor).

Jaundice induced by 17 α ethyl-19-nortestosterone (Nilevar)

7. Dunning, M.F. Jaundice associated with norethandrolone (Nilevar) administration. J. Amer. Med. Assoc. 167:1242-1243, 1958.

8. Shaw, R.K. and Gold, G.L. Jaundice associated with norethandrolone (Nilevar) therapy. Ann. Int. Med. 52:428-434, 1960.

9. Gilbert, E.F., DaSilva, A.Q., and Queen, D.M. Intrahepatic cholestasis with fatal termination following norethandrolone therapy. J. Amer. Med. Assoc. 185:538-539, 1963.

Liver function, particularly 45-minute BSP test, frequently affected in patients taking anabolic steroids

10. Dowben, R.M. Effect of norethandrolone on serum enzyme levels. J. Clin. Endocrinol. 18:1308-1309, 1958 (Letter to editor).

11. Kory, R.C., Bradley, M.H., Watson, R.N., Callahan, R. and B.J. Peters. A six-month evaluation of an anabolic drug, norethandrolone, in underweight persons. II. Bromsulphalein (BSP) rentetion and liver function. Amer. J. Med. 26:238-248, 1959.

12. Marquardt, G.H., Fisher, C.I., Levy, P. and Dowben, R.M. Effect of anabolic steroids on liver function tests and creatine excretion. J. Amer. Med. Assoc. 175:851-853, 1961.

13. Wynn, V., Landon, J., and Kawerau, E. Studies of hepatic function during methandienone therapy. Lancet Jan. 14, 1961, 69-75.

14. Marquardt, G.H., Logan, C.E., Tomhave, W.G., and Dowben, R.M. Failure of non-17-alkylated anabolic steroids to produce abnormal liver function tests. J. Clin. Endocrinol. and Metabol. 24:1334-1336, 1964.

15. deLorimier, A.A., Gordan, G.S., Lowe, R.C., and Carbone, J.V. Methyltestosterone, related steroids, and liver function. Arch. Intern. Med. 116:289-294, 1965.

16. Heaney, R.P. and Whedon, G.D. Impairment of hepatic bromsulphalein clearance by two 17-substituted testosterones. J. Lab. Clin. Med. 52:169-175, 1958.

17. Leevy, C.M., Cherrick, G.R., and Davidson, C.S. Observations on norethandrolone-induced abnormalities in plasma decay of sulfobromophthalein and indocyanine green. J. Lab. Clin. Med. 57:918-926, 1961.

Hepatic pathology produced by Nilevar

18. Schaffner, F., Popper, H., and Chesrow, E. Cholestasis produced by the administration of norethandrolone. Amer. J. Med. 26:249-254, 1959.

19. Schaffner, F., Popper, H., and Perez, V. Changes in bile canaliculi produced by norethandrolone: electron microscopic study of lumen and rat liver. J. Lab. Clin. Med. 56: 623-628, 1960.

Cholestatic jaundice of pregnancy

20. Svanborg, A., and Ohlsson, S. Recurrent jaundice of pregnancy. Amer. J. Med. 27:40-49, 1959.

21. Thorling, L. Jaundice in pregnancy. A clinical study. Acta Med. Scand. Suppl. 302, 1955.

22. Ikonen, E. Jaundice in late pregnancy. Acta Obstet. et Gynecol. Scand. 63, 1964.

23. Haemmerli, U.P. Jaundice During Pregnancy. Springer-Verlag, New York, 1967.

24. Haemmerli, U.P. and Wyss, H.I. Recurrent intrahepatic cholestasis of pregnancy. Med. 46:299-321, 1967.

25. Adlercreutz, H., Svanborg, A., and Anberg, A. Recurrent jaundice in pregnancy. I. A clinical and ultrastructural study. Amer. J. Med. 42:335-340, 1967.

26. Adlercreutz, H., Svanborg, A., and Anberg, A. Recurrent jaundice in pregnancy. II. A study of the estrogens and their conjugation in late pregnancy. Amer. J. Med. 42:341-347, 1967.

Analysis of hepatic BSP removal mechanisms

MOVEMENT OF BSP FROM BLOOD TO BILE



27. Wheeler, H.O., Meltzer, J.I., and Bradley, S.E. Biliary transport and hepatic storage of sulfobromophthalein sodium in unanesthetized dog, in normal man, and in patients with hepatic disease. J. Clin. Invest. 39:1131-1144, 1960.

28. Combes, B. Excretory function of the liver. In The Liver, Vol. 2, Academic Press Inc., New York, 1964.

BSP removal from blood in normal pregnancy

29. Combes, B., Shibata, H., Adams, R., Mitchell, B.D., and Trammell, V. Alterations in sulfobromophthalein sodium-removal mechanisms from blood during normal pregnancy. J. Clin. Invest. 42:1431-1442, 1963.

Effect of estrogens on hepatic BSP removal mechanisms

30. Mueller, M.N. and Kappas, A. Estrogen pharmacology. I. The influence of estradiol and estriol on hepatic disposal of sulfobromophthalein (BSP) in man. J. Clin. Invest. 43:1905-1914, 1964.

31. Gallagher, T.F., Mueller, M.N. , and Kappas, A. Studies on the mechanism and structural specificity of the estrogen effect on BSP metabolism. Trans. Assoc. Amer. Phys. 48:187-195, 1965.

32. Kottra, L.L. and Kappas, A. Estrogen Pharmacology. III. Effect of estradiol on plasm disappearance rate of sulfobromophthalein in man. Arch. Intern. Med. 117:373-376, 1966.

33. Gallagher, T.F., Mueller, M.N., and Kappas, A. Estrogen pharmacology. IV. Studies on the structural basis for estrogen-induced impairment of liver function. Med. 45:471-479, 1966.

34. Kappas, A. Estrogens and the liver. Gastroenterol. 52:113-116, 1967 (Editorial).

Effect of 17 α-ethyl-19-nortestosterone on hepatic BSP removal mechanisms

35. Scherb, J., Kirschner, M., and Arias, I. Studies of hepatic excretory function. The effect of 17 α-ethyl-19-nortestosterone on sulfobromophthalein sodium (BSP) metabolism in man. J. Clin. Invest. 42:404-408, 1963.

36. Schoenfield, L.J., and Foulk, W.T. Studies of sulfobromophthalein sodium (BSP) metabolism in man. II. The effect of artificially induced fever, norethandrolone (Nilevar), and iopanoic acid (Telapaque). J. Clin. Invest. 43:1419-1423, 1964.

Effect of steroids on BSP-glutathione conjugation

37. Goldstein, J., and Combes, B. The effect of steroids on the activity of the enzyme that catalyzes sulfobromophthalein-glutathione conjugation. J. Lab. Clin. Med. 67:830-835, 1966.

ORAL CONTRACEPTIVE AGENTS COMMERCIALLY AVAILABLE*

Pill	Progestogen		Estrogen	
		mg		µg
Combination type				
Enovid (Searle)	Norethynodrel	9.85	EE3ME	150
Enovid (Searle)	Norethynodrel	5.0	EE3ME	75
Enovid E (Searle)	Norethynodrel	2.5	EE3ME	100
Ovulen (Searle)	Ethynodiol diacetate	1.0	EE3ME	100
Ortho-Novum (Ortho)	Norethindrone	10.0	EE3ME	60
Ortho-Novum (Ortho)	Norethindrone	2.0	EE3ME	100
Norinyl (Syntex)	Norethindrone	2.0	EE3ME	100
Norlestrin (Parke, Davis)	Norethindrone acetate	2.5	EE	50
Provest (Upjohn)	Medroxyprogesterone acetate	10.0	EE	50
Sequential type				
Oracon (Mead Johnson)	Dimethisterone (last 5 days)	25.0	EE	100
C-Quens (Lilly)	Chlormadinone (last 5 days)	2.0	EE3ME	80
Ortho-Novum SQ (Ortho)	Norethindrone (last 6 days)	2.0	EE3ME	80

* EE3ME = mestranol; EE = ethinyl estradiol.

TESTOSTERONE



17 α METHYL
TESTOSTERONE



17 α METHYL
19 NORTESTOSTERONE



17 α ETHYL
19 NORTESTOSTERONE
(NILEVAR)



9 α FLUORO-11β HYDROXY-17 α METHYL
TESTOSTERONE
(FLUOXYMESTERONE)



17 α ETHYNYL
19 NORTESTOSTERONE
(NORETHINDRONE)



17 α ETHYNYL
Δ5,10-ESTREN-17-OL-3-ONE
(NORETHYNODREL)



ESTRADIOL



17 α ETHYNYL
ESTRADIOL



MESTRANOL



Effects of oral contraceptive agents on the liver

38. Perez-Mera, R.A., and Shields, C.E. Jaundice associated with norethindrone acetate therapy. New Eng. J. Med. 267:1137-1138, 1962.

39. Eisalo, A., Jarvinen, P.A., and Luukkainen, T. Hepatic impairment during the intake of contraceptive pills: clinical trial with postmenopausal women. Brit. Med. J. 2:426-427, 1964.

40. Tyler, E.T. Eight years' experience with oral contraception and an analysis of use of low-dosage norethesterone. Brit. Med. J. 2:843-847, 1964.

41. Linthorst, G. Liver function after long-term progestational treatment with and without estrogen. Brit. Med. J. 2:920-921, 1964.

42. Elliott, A.J., and Hendry, J. Cholestatic jaundice complicating pregnancy: recurrence after norethynodrel with ethynylestradiol (Enovid). Canad. Med. Ass. J. 92:344-345, 1965.

43. Bakke, J.L. Hepatic impairment during intake of contraceptive pills: observations in post-menopausal women. Brit. Med. J. 1:631-632, 1965.

44. Cullberg, G., Lundstrom, R., and Stenram, U. Jaundice during treatment with an oral contraceptive, lyndiol. Brit. Med. J. 1:695-697, 1965.

45. Borglin, N.E. Oral contraceptives and liver damage. Brit. Med. J. 1:1289-1290, 1965.

46. Swyer, G.I.M. and Little, V. Absence of hepatic impairment in long-term oral-contraceptive users. Brit. Med. J. 1:1412-1414, 1965.

47. Larsson-Cohn, U. Oral contraception and liver-function tests. Brit. Med. J. 1:1414-1415, 1965.

48. Eisalo, A., Jarvinen, P.A., and Luukkainen, T. Liver-function tests during intake of contraceptive tablets in pre-menopausal women. Brit. Med. J. 1:1416-1417, 1965.

49. Boake, W.C., Schade, S.G., Morrissey, J.F., and Schaffner, F. Intrahepatic cholestatic jaundice of pregnancy followed by Enovid-induced choestatic jaundice. Ann. Int. Med. 63:302-308, 1965.

50. Larsson-Cohn, U., and Stenram, U. Jaundice during treatment with oral contraceptive agents. J. Amer. Med. Assoc. 193:422-426, 1965.

51. Thulin, K.E., and Nermark, J. Seven cases of jaundice in women taking an oral contraceptive Anovlar. Brit. Med. J. 1:584-586, 1966.

52. Orellana-Alcalde, J.M., and Dominguez, J.P. Jaundice and oral contraceptive drugs. Lancet,Dec. 10, 1966.

53. Larsson-Cohn, U. Jaundice and oral contraceptives. Lancet 1:679, 1967.

54. Larsson-Cohn, U., and Stenram, U. Liver ultrastructure and function in icteric and non-icteric women using oral contraceptive agents. Acta Med. Scand. 181:257-264, 1967.

55. Schaffner, F. The effect of oral contraceptives on the liver. J. Amer. Med. Assoc. 198:1019-1021, 1966.

56. Ockner, R.K., and Davidson, C.S. Hepatic effects of oral contraceptives. New Eng. J. Med. 276:331-334, 1967.

57. Allan, J.S., and Tyler, E.T. Biochemical findings in long-term oral contraceptive usage. I. Liver function studies. Fertility and Sterility 18:112-123, 1967.

58. Kleiner, G.J., Kresch, L., and Arias, I.M. Studies of hepatic excretory function. II. The effect of norethynodrel and mestranol on bromsulfalein sodium metabolism in women of childbearing age. New Eng. J. Med. 273:420-423, 1965.

59. Kottra, J., and Kappas, A. Steroid effects of hepatic function: recent observations. Ann. Rev. Med. 18:325-332, 1967.

Conversion of progestin to estrogen

60. Breuer, H. Studies on the metabolism of 17 α-ethinyl-19-nortestosterone. Int. J. Fertil. 9:181-187, 1964.

61. Paulsen, C.A. Progestin metabolism: special reference to estrogenic pathways. Metabol. 14:313-319, 1965.

Additional adverse reactions to oral contraceptive agents, imagined, possible, real

62. Oral contraceptives and thromboembolic disease. Leading Article, Brit. Med. J. 2:327-328, 1967.

63. Oral contraceptives and thromboembolism. Leading Article, Lancet, May 13, 1967, 1039-1040.

64. Haynes, R.L., and Dunn, J.M. Oral contraceptives, thrombosis, and sickle cell hemoglobinopathies. J. Amer. Med. Assoc. 200:994-996, 1967.

65. Jennett, W.B., and Cross, J.N. Influence of pregnancy and oral contraception on the incidence of strokes in women of childbearing age. Lancet, May 13, 1967, 1019-1023.

66. Laragh, J.H., Sealey, J.E., Ledingham, J.G.G., and Newton, M.A. Oral contraceptives. Renin, aldosterone, and high blood pressure. J. Amer. Med. Assoc. 201:918-922, 1967.

67. Woods, J.W. Oral contraceptives and hypertension. Lancet, Sept. 23, 1967, 653-656.

68. Wynn, V., and Doar, J.W.H. Some effects of oral contraceptives on carbohydrate metabolism. Lancet, Oct. 1, 1966, 715-719.

69. Wynn, V., Doar, J.W.H., and Mills, G.L. Some effects of oral contraceptives on serum-lipid and lipoprotein levels. Lancet, Oct. 1, 1966, 720-723.

70. Posner, N.A., Silverstone, F.A., Pomerance, W., and Baumgold, D. Oral contraceptives and intravenous glucose tolerance. I. Data noted early in treatment. Obstet. and Gynec. 29:79-86, 1967.

71. Posner, N.A., Silverstone, F.A., Pomerance, W., and Singer, N. Oral contraceptives and intravenous glucose tolerance. II. Long-term effect. Obstet. and Gynec. 29:87-92, 1967.

72. Spellacy, W.N., Carlson, K.L., and Schade, S.L. Human growth hormone levels in normal subjects receiving an oral contraceptive. J. Amer. Med. Assoc. 202:451-454, 1967.

73. Resnik, S. Melasma induced by oral contraceptive drugs. J. Amer. Med. Assoc. 199: 601-605, 1967.

74. Watson, W.C., and D. Murray. Lactase deficiency and jejunal atrophy associated with administration of conovid. Lancet, Jan. 8, 1966, 65-67.

75. Cormia, F.E. Alopecia from oral contraceptives. J. Amer. Med. Assoc. 201:635-637, 1967.

76. Hertz, R., and Bailar, J.C. III. Estrogen-progestogen combinations for contraception. J. Amer. Med. Assoc. 198:1000-1006, 1966.